BR112012002265A2 - composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios - Google Patents
composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbiosInfo
- Publication number
- BR112012002265A2 BR112012002265A2 BR112012002265A BR112012002265A BR112012002265A2 BR 112012002265 A2 BR112012002265 A2 BR 112012002265A2 BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 A2 BR112012002265 A2 BR 112012002265A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- cancer
- diseases
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021209P | 2009-07-31 | 2009-07-31 | |
| US61/230,212 | 2009-07-31 | ||
| PCT/US2010/002109 WO2011014248A1 (en) | 2009-07-31 | 2010-07-28 | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012002265A2 true BR112012002265A2 (pt) | 2016-06-14 |
| BR112012002265B1 BR112012002265B1 (pt) | 2021-01-12 |
| BR112012002265B8 BR112012002265B8 (pt) | 2021-05-25 |
Family
ID=42697590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002265A BR112012002265B8 (pt) | 2009-07-31 | 2010-07-28 | composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20110039826A1 (pt) |
| EP (1) | EP2459173B1 (pt) |
| JP (2) | JP2013500965A (pt) |
| KR (1) | KR101762285B1 (pt) |
| CN (2) | CN102548539A (pt) |
| AR (1) | AR077436A1 (pt) |
| AU (1) | AU2010276741B2 (pt) |
| BR (1) | BR112012002265B8 (pt) |
| CA (1) | CA2769531C (pt) |
| CL (1) | CL2012000261A1 (pt) |
| CO (1) | CO6612185A2 (pt) |
| CR (1) | CR20120084A (pt) |
| EA (1) | EA025277B1 (pt) |
| EC (1) | ECSP12011703A (pt) |
| GE (1) | GEP201606513B (pt) |
| IL (1) | IL217839A (pt) |
| IN (1) | IN2012DN01237A (pt) |
| JO (1) | JO3434B1 (pt) |
| MA (1) | MA33533B1 (pt) |
| MX (2) | MX2012001196A (pt) |
| MY (1) | MY174084A (pt) |
| NZ (1) | NZ598096A (pt) |
| PE (1) | PE20120788A1 (pt) |
| SG (2) | SG10201404483VA (pt) |
| TN (1) | TN2012000046A1 (pt) |
| TW (1) | TWI522357B (pt) |
| UA (1) | UA110463C2 (pt) |
| UY (1) | UY32822A (pt) |
| WO (1) | WO2011014248A1 (pt) |
| ZA (1) | ZA201200944B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE381566T1 (de) * | 2004-05-14 | 2008-01-15 | Millennium Pharm Inc | Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase |
| US20100183601A1 (en) | 2008-12-22 | 2010-07-22 | Millennium Pharmaceuticals, Inc. | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| TWI392514B (zh) * | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
| CN104031049A (zh) | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂的结晶形式 |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| JP6525474B2 (ja) | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用 |
| USD797120S1 (en) | 2015-08-28 | 2017-09-12 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with graphical user interface |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| CN101259270A (zh) | 1999-08-11 | 2008-09-10 | 拜奥根Idec公司 | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 |
| KR20030019327A (ko) * | 2000-03-24 | 2003-03-06 | 아이박스 리서치 인코포레이티드 | 탁산-기저 조성물을 안정시키는 금속염의 용도 |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| ATE381566T1 (de) * | 2004-05-14 | 2008-01-15 | Millennium Pharm Inc | Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| SI1962830T1 (sl) * | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
| CN101511361A (zh) | 2006-06-30 | 2009-08-19 | 先灵公司 | 使用增强p53活性的取代哌啶的方法 |
| CN101516335B (zh) * | 2006-07-21 | 2014-01-08 | 诺瓦提斯公司 | 苯并咪唑基吡啶基醚的制剂 |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) * | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| US20100183601A1 (en) * | 2008-12-22 | 2010-07-22 | Millennium Pharmaceuticals, Inc. | Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| CN104031049A (zh) * | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂的结晶形式 |
-
2010
- 2010-07-26 JO JOP/2010/0264A patent/JO3434B1/ar active
- 2010-07-28 EA EA201270205A patent/EA025277B1/ru unknown
- 2010-07-28 MX MX2012001196A patent/MX2012001196A/es not_active Application Discontinuation
- 2010-07-28 NZ NZ59809610A patent/NZ598096A/en unknown
- 2010-07-28 PE PE2012000132A patent/PE20120788A1/es not_active Application Discontinuation
- 2010-07-28 MY MYPI2012000438A patent/MY174084A/en unknown
- 2010-07-28 AU AU2010276741A patent/AU2010276741B2/en active Active
- 2010-07-28 CN CN2010800415230A patent/CN102548539A/zh active Pending
- 2010-07-28 EP EP10739413.2A patent/EP2459173B1/en active Active
- 2010-07-28 CA CA2769531A patent/CA2769531C/en active Active
- 2010-07-28 SG SG10201404483VA patent/SG10201404483VA/en unknown
- 2010-07-28 SG SG2012005401A patent/SG177751A1/en unknown
- 2010-07-28 UA UAA201202214A patent/UA110463C2/ru unknown
- 2010-07-28 CN CN201410112836.0A patent/CN103893186B/zh active Active
- 2010-07-28 JP JP2012522810A patent/JP2013500965A/ja active Pending
- 2010-07-28 BR BR112012002265A patent/BR112012002265B8/pt active IP Right Grant
- 2010-07-28 US US12/844,920 patent/US20110039826A1/en not_active Abandoned
- 2010-07-28 WO PCT/US2010/002109 patent/WO2011014248A1/en active Application Filing
- 2010-07-28 MX MX2015002869A patent/MX348197B/es unknown
- 2010-07-28 IN IN1237DEN2012 patent/IN2012DN01237A/en unknown
- 2010-07-28 KR KR1020127004651A patent/KR101762285B1/ko active IP Right Grant
- 2010-07-28 GE GEAP201012599A patent/GEP201606513B/en unknown
- 2010-07-30 AR ARP100102812 patent/AR077436A1/es not_active Application Discontinuation
- 2010-07-30 TW TW099125531A patent/TWI522357B/zh active
- 2010-08-02 UY UY32822A patent/UY32822A/es not_active Application Discontinuation
-
2012
- 2012-01-27 TN TNP2012000046A patent/TN2012000046A1/en unknown
- 2012-01-30 IL IL217839A patent/IL217839A/en active IP Right Grant
- 2012-01-31 CL CL2012000261A patent/CL2012000261A1/es unknown
- 2012-02-08 ZA ZA2012/00944A patent/ZA201200944B/en unknown
- 2012-02-09 CO CO12022583A patent/CO6612185A2/es not_active Application Discontinuation
- 2012-02-16 MA MA34640A patent/MA33533B1/fr unknown
- 2012-02-17 CR CR20120084A patent/CR20120084A/es unknown
- 2012-02-29 EC ECSP12011703 patent/ECSP12011703A/es unknown
-
2013
- 2013-06-11 US US13/914,705 patent/US9127011B2/en active Active
-
2015
- 2015-02-05 JP JP2015021023A patent/JP6014695B2/ja active Active
- 2015-08-28 US US14/838,878 patent/US9504693B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012002265A2 (pt) | composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| IL245889A0 (en) | Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases | |
| BRPI0917444A2 (pt) | composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc | |
| SMT201600055B (it) | Composizione farmaceutica per il trattamento o la prevenzione del glaucoma | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| BRPI1006116A2 (pt) | "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes". | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| EP2125855A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | |
| BRPI1006115A2 (pt) | "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes". | |
| BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
| BR112013015859A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| BRPI1008566A8 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| BRPI1014759A2 (pt) | composto útil para o tratamento de doenças degenerativas e inflamatórias | |
| BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
| BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| IL224215A (en) | An integrated drug for the treatment of functional diseases or conditions of the gastrointestinal system | |
| BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| BRPI1009448A2 (pt) | combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| BR112013015877A2 (pt) | composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |